Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
RESEARCH TOOLSreports
Holding MRSN?
Track your performance easily
MRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.22 - $6.28
Previous Close$1.98
Volume587.91K
Average Volume (3M)1.02M
Market Cap
$244.60M
Enterprise Value$197.23M
Total Cash (Recent Filing)$78.87M
Total Debt (Recent Filing)$31.50M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Feb 26, 2025EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding123,532,909
10 Day Avg. Volume1,694,962
30 Day Avg. Volume1,024,419
Standard Deviation0.36
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)222.00
Price to Sales (P/S)7.87
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.66
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$6.33Price Target Upside210.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Mersana Therapeutics News
PremiumCompany Announcements
Mersana Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Mersana Therapeutics Reports Progress in Cancer Treatments
PremiumCompany Announcements
Mersana Therapeutics Releases Updated Corporate PresentationBulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe ongoing dose escalation in the Phase I for XMT-1660 has reached 115mg/m without yet having reached the maximum tolerated dose.
Market OpportunityAnalyst sees a meaningful market opportunity for Mersana Therapeutics in differentiating its XMT-1660 from competitor B7-H4 ADCs by focusing on safety and potential combination regimens.
Valuation OutlookThe valuation of Mersana Therapeutics has been updated with a lower discount rate and a higher terminal growth rate, indicating a positive outlook.
Bears Say
Competitive DifferentiationAnalyst remains cautious that this early XMT-1660 readout will show differentiation versus its three large pharma competitors.
Investor SentimentThe stock remains a 'show-me' story to investors, many of whom feel burned by last year's UpRi updates and prior management's messaging into those events.
Safety ConcernsSafety signals included 55% Grade 3+ adverse events, 15% rate of serious adverse events across all doses, 37% rate of Grade 3+ neutropenia, and 2% rate of Grade 5 treatment-related adverse events.
---
Ownership Overview
8.38% Insiders
9.10% Mutual Funds
55.20% Other Institutional Investors
16.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $1.22 and its highest was $6.28 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Currently, no data Available
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on Nov 13, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.082.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -$0.15.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 123,532,906 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 19.545%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Among the largest hedge funds holding Mersana Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Mersana Therapeutics Inc’s shares valued at 2M.
---
Mersana Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (210.29% Upside)
$6.33 (210.29% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 25.7%
Last 30 Days ▲ 56.4%
Last 30 Days ▲ 56.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.31%
12-Months-Change
Fundamentals
Return on Equity
-280.29%
Trailing 12-Months
Asset Growth
-35.52%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
---
MRSN Earnings Call
Q3 2024
0:00 / 0:00
---
MRSN Stock 12 Month Forecast
Average Price Target
$6.33
▲(210.29% Upside)
Technical Analysis
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-4.32%
upgraded a buy rating 9 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.32% per trade.
---